Laparoscopy

Medical Microinstruments Launches New Simulator for Robotic Microsurgery

Retrieved on: 
Thursday, May 26, 2022
Gynaecology, Spondyloarthropathy, VP, European Association of Urology, Surgeon, Multimedia, Patient, Tremor, Health, Solution, Association, MMI, Robotics, English, Elective surgery, Urology, Obstetrics, Marketing, Plastic, Technology, Ligation, Laparoscopy, Microsurgery, CEO, Medical device, Dentistry, Online shopping, VirtaMed

PISA, Italy, May 26, 2022 /PRNewswire/ -- Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed. The simulator will improve, expand, and digitize the pathways for Symani training as surgeons prepare to expand their microsurgical skills through robotics.

Key Points: 
  • PISA, Italy, May 26, 2022 /PRNewswire/ -- Medical Microinstruments (MMI) SpA , a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed.
  • The simulator will improve, expand, and digitize the pathways for Symani training as surgeons prepare to expand their microsurgical skills through robotics.
  • "By training on the simulator, surgeons will be even more prepared for their first Symani patient or for a challenging case."
  • Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery.

Medical Microinstruments Launches New Simulator for Robotic Microsurgery

Retrieved on: 
Thursday, May 26, 2022
Gynaecology, Spondyloarthropathy, VP, European Association of Urology, Surgeon, Patient, Tremor, Health, Solution, Association, MMI, Robotics, English, Elective surgery, Urology, Obstetrics, Marketing, Plastic, Technology, Ligation, Laparoscopy, Microsurgery, CEO, Medical device, Dentistry, Online shopping, VirtaMed

PISA, Italy, May 26, 2022 /PRNewswire/ -- Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed. The simulator will improve, expand, and digitize the pathways for Symani training as surgeons prepare to expand their microsurgical skills through robotics.

Key Points: 
  • PISA, Italy, May 26, 2022 /PRNewswire/ -- Medical Microinstruments (MMI) SpA , a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed.
  • The simulator will improve, expand, and digitize the pathways for Symani training as surgeons prepare to expand their microsurgical skills through robotics.
  • "By training on the simulator, surgeons will be even more prepared for their first Symani patient or for a challenging case."
  • Medical Microinstruments S.p.A. (MMI) was founded in 2015 near Pisa, Italy to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery.

Olympus Supports CMS Coverage Decision for Lung Cancer Screening

Retrieved on: 
Tuesday, May 24, 2022
People, Laparoscopy, Disease, Method, Lung cancer, American College of Chest Physicians, PJ, Olympus Corporation, Center, Lymph, Lammers, Physician, Rose M. Likins, Medicaid, Lung, American Lung Association, Quality of life, Ultrasound, NSCLC, Research, Medicare, Neoplasm, Large-cell lung carcinoma, PMID, Centers for Medicare & Medicaid Services, CMS, American College, Survival, CM, Multimedia, Smoker, Mediastinoscopy, Endoscopy, EBUS, Awareness, Kątki, Mediastinum, United States Preventive Services Task Force, Olympus, Patient, User experience, Survival rate, Decision-making, USPSTF, Lung cancer staging, Veni, vidi, vici, Prognosis, Diagnosis, Health insurance, Medical imaging, Medical device, Mobile phone, Silviculture, Medicine

CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.

Key Points: 
  • CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.
  • Earlier screening and detection may save the lives of those diagnosed with non-small cell lung cancer," said Paul Skodny, Executive Director of Global Health Economics and Market Access at Olympus Corporation of the Americas.
  • "Still, there is much work to be done to align CMS coverage through Medicare and Medicaid with lung cancer screening guidance so that the barriers to screening are eliminated."
  • Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Olympus Announces Exclusive U.S. Co-Marketing Agreement with Bracco Diagnostics, Inc.

Retrieved on: 
Thursday, May 19, 2022
Storm, Physician, Laparoscopy, EUS, Olympus, Fair Employment Practice Committee, Porter Adventist Hospital, Nausea, Hypersensitivity, Radiation, Sulfur hexafluoride, DDW, Multimedia, Patient, Quality of life, Constance J. Chang-Hasnain, Liver, Microparticle, Bleeding, Endoscopy, Bracco (company), Awareness, Liver disease, Center, Safety, Pathology, Headache, GI, Diagnosis, PMID, Microbubble, Perforation, Medical device, Medical imaging, Pharmaceutical industry, Medicine

CENTER VALLEY, Pa., May 19, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today a strategic co-marketing agreement with Monroe Township, N.J.-based Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business. Through this agreement, Olympus and Bracco will work together to raise awareness of the role of endoscopic ultrasound (EUS) with contrast in the characterization of focal liver lesions. The contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) technology will open pathways for more innovative and timely diagnosis and treatment of liver disease.

Key Points: 
  • Through this agreement, Olympus and Bracco will work together to raise awareness of the role of endoscopic ultrasound (EUS) with contrast in the characterization of focal liver lesions.
  • More detailed visualization during minimally invasive procedures can provide more information to physicians for use in diagnosis.
  • Per the terms of the agreement, Olympus will co-market the Lumason ultrasound enhancing agent with Bracco Diagnostics, Inc. Risks associated with the use of Lumason include headache and nausea.
  • "We gain from this agreement an additional pathway to discuss with physicians the importance of better specificity in diagnosing liver malignancies.

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
Wednesday, May 18, 2022
Urination, Laparoscopy, Olympus, Quality of life, Quality, Blood, Urine, Time-invariant system, Multimedia, Patient, Prostate, View, BPH, International Prostate Symptom Score, Clinical study design, Treatment, Endoscopy, Urology, DOI, EMEA, IPSS, Man, Lower urinary tract symptoms, AUA, University, Ageing, Olympus Corporation, Urinary tract infection, MD, University of Turin, Medical imaging, Medical device

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
Wednesday, May 18, 2022
Urination, Laparoscopy, Olympus, Quality of life, Quality, Blood, Urine, Time-invariant system, Patient, Prostate, BPH, International Prostate Symptom Score, Clinical study design, Treatment, Endoscopy, Urology, DOI, EMEA, IPSS, Man, Lower urinary tract symptoms, AUA, University, Ageing, Olympus Corporation, Urinary tract infection, MD, University of Turin, Medical imaging, Medical device

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .

iTind Procedure Wins Gold and Silver Medtech Awards

Retrieved on: 
Friday, May 13, 2022
Laparoscopy, Edison Awards, Olympus, Engineering, Blood, Association for the Behavioral Sciences and Medical Education, Urine, Medicine, Multimedia, Prostate, Patient, Science, Solution, BPH, Quality of life, Treatment, Endoscopy, Urology, Man, Safety, Emergency Medical Treatment and Active Labor Act, Gastrointestinal tract, Olympus Corporation, Urinary tract infection, Gold, Medical device, Pharmaceutical industry, Medical imaging, Birth control, Silver

CENTER VALLEY, Pa., May 13, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today that its iTind™ procedure for the treatment of enlarged prostate won Gold in the 2022 Medical Design Excellence Awards and Silver in the 2022 Edison Awards.

Key Points: 
  • CENTER VALLEY, Pa., May 13, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today that its iTind procedure for the treatment of enlarged prostate won Gold in the 2022 Medical Design Excellence Awards and Silver in the 2022 Edison Awards.
  • Nominated within the Science and Medical category for Medical Treatments, the iTind procedure was recognized by the Edison Awards, which highlights innovation and innovators whose solutions make a positive impact in the world.
  • Treatment with the iTind procedure takes five to seven days and works by reshaping the prostate.
  • As with any medical procedure, the iTind procedure comes with possible side effects, including pelvic discomfort, blood in urine, painful or urgent urination.

Global Prepackaged Medical Kits and Trays Market Report 2022: Market to Reach $36.6 Billion by 2026 - Waste Minimization Focus Drives Manufacturers to Reformulate Kits - ResearchAndMarkets.com

Retrieved on: 
Friday, May 13, 2022
Medical Supplies, Health, Risk, Population, Infection, ENT, IV, COVID-19, Urology, Growth, Hospital, Safety, Ageing, Adoption, CAGR, Laparoscopy, Animal, Pet, Pharmaceutical industry, Video game, Tray

The "Prepackaged Medical Kits and Trays - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prepackaged Medical Kits and Trays - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Growing infection control requirements and an aging population are the key growth drivers for prepackaged medical disposables including kits and trays.
  • The market is flooded with a vast range of products with customized packages for almost every type of invasive procedure.
  • This segment currently accounts for a 14.3% share of the global Prepackaged Medical Kits and Trays market.

Global Medical Robotics Market Report 2022: Breakdown by Surgical Robotic Systems, Rehabilitation Robotic Systems, & Hospital & Pharmacy Robotic Systems - Forecast to 2027

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Rehabilitation, Lists of diseases, Projection, Robotics, Vision Guided Robotic Systems, Prevalence, Patient, Coronavirus, Person, Hospital, Artificial intelligence, Industry, Conditional sentence, Adoption, CAGR, Research, Dominance, Medicine, Medical device, Health insurance, Animal, Laparoscopy, Neurosurgery, Pharmacy, Growth

Furthermore, surgical robots are becoming more efficient in performing laparoscopic surgical procedures, and new and upgraded procedure-specific robots are being introduced to the global market.

Key Points: 
  • Furthermore, surgical robots are becoming more efficient in performing laparoscopic surgical procedures, and new and upgraded procedure-specific robots are being introduced to the global market.
  • The global benefits of robotic-assisted surgery and robot-assisted training in rehabilitation therapy, technological advancements in robotic systems, improving reimbursement scenarios, increasing adoption of surgical robots, and increased funding for medical robot research are all driving the growth of the global medical robotics market.
  • As a result, the worldwide medical robots market is expanding rapidly and is likely to continue in the coming years.
  • The Major Factors That Determine the Surgical Robots Segment's Dominance:
    Surgical Robotic Systems, Rehabilitation Robotic Systems, Hospital & Pharmacy Robotic Systems, and Non-invasive Radiosurgery Robotic Systems are the market segments in the analysis based on product.

Global Medical Robotics Market Report 2022: Trends, Growth, Outlook, Impact of COVID-19, Company Analysis, 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 29, 2022
Surgery, Hardware, Other Health, Health, Technology, Medicine, Artificial intelligence, Patient, Rehabilitation, COVID-19, Prevalence, Projection, Person, Adoption, Conditional sentence, CAGR, Robotics, Lists of diseases, Vision Guided Robotic Systems, Research, Hospital, Coronavirus, Industry, Dominance, Pharmaceutical industry, Medical device, Health insurance, Animal, Pharmacy, Growth, Laparoscopy, Neurosurgery

The "Global Medical Robotics Market, Size, Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Robotics Market, Size, Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Furthermore, surgical robots are becoming more efficient in performing laparoscopic surgical procedures, and new and upgraded procedure-specific robots are being introduced to the global market.
  • The global benefits of robotic-assisted surgery and robot-assisted training in rehabilitation therapy, technological advancements in robotic systems, improving reimbursement scenarios, increasing adoption of surgical robots, and increased funding for medical robot research are all driving the growth of the global medical robotics market.
  • As a result, the worldwide medical robots market is expanding rapidly and is likely to continue in the coming years.